- Research article
- Open Access
Novel heteroaryl phosphonicdiamides PTPs inhibitors as anti-hyperglycemic agents
© Sekhar et al.; licensee BioMed Central. 2014
- Received: 20 March 2014
- Accepted: 13 November 2014
- Published: 27 December 2014
Chronic and oral administration of benzylamine improves glucose tolerance. Picolylamine is a selective functional antagonist of the human adenosine A2B receptor. Phosphonic diamide derivatives enhance the cellular permeability and in turn their biological activities.
A series of heteroaryl phosphonicdiamide derivatives were designed as therapeutics to control and manage type2 diabetes. Initially defined Lipinski parameters encouraged them as safer drugs. Molecular docking of these compounds against Protein tyrosine phosphatase (PTP), the potential therapeutic target of type 2 diabetes, revealed their potential binding ability explaining their anti-diabetic activity in terms of PTP inhibition. Human intestinal absorption, Caco-2 cell permeability, MDCK cell permeability, BBB penetration, skin permeability and plasma protein binding abilities of the title compounds were calculated by PreADMET server. A convenient method has been developed for the synthesis of title compounds through the formation of 1-ethoxy-N,N’-bis(4-fluorobenzyl/pyridin-3-ylmethyl)phosphinediamine by the reaction of 4-fluorobenzylamine/ 3-picolylamine with ethyldichlorophosphite, subsequently reacted with heteroaryl halides using lanthanum(III) chloride as a catalyst.
All the compounds exhibited significant in vitro anti-oxidant activity and in vivo evaluation in streptozotocin induced diabetic rat models revealed that the normal glycemic levels were observed on 12th day by 9a and 20th day by 5b, 5c, 9e and 9f. The remaining compounds also exhibited normal glycemic levels by 25th day.
- Title Compound
- Protein Tyrosine Phosphatase
- DPPH Radical Scavenge Activity
- Glycemic Level
The study of the reported drugs i-vii reveals that they are ideal for anti-diabetic activity due to the thiazolidine-2,4-dione (i, ii, iii), pyridinyl (i,ii), quinolone (iv), urea and amide (v, vii), Flouro substituted, heteroaryl pyrazine (vi) and benzyl amine (vii). Compound xiii is a α-aminophosphonate with established anti-diabetic property which gave an idea to focus on phosphorus containing drugs.
Benzylamine is used to treat diabetes in traditional medicine. Chronic and oral administration of benzylamine improves glucose tolerance and the circulating lipid profile without increasing oxidative stress in overweight and pre-diabetic mice . The stipulation of picolylamine was attested in the synthesis of various pharmacological compounds such as 99mTc(I)-complexs  and selective functional antagonists of the human adenosine A2B receptor . When compared to normal benzyl amine analogues, picolylamine analogues are exhibiting the potential pharmacological activity . Among the 2-picolyl, 3-picolyl and 4-picolyl amines, the performance of 3-picolyl amines are virtuous .
Phosphonic diamide derivatives enhance the cellular permeability and in turn their activities akin to the analogous phosphoric diamide prodrugs of 3′-azido-3′-deoxythymidine (AZT) monophosphate with AZT , glycine methyl ester phosphonic diamide of a 9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA) analogue , and diamides of 9-[2-(phosphonomethoxy)ethyl]-N6-(cyclopropyl)-2-aminoadenine . If phosphonic diamides hydrolyze in vivo to produce phosphonic acids benzyl amine itself act as antidiabetic agent . Phosphonic diamide derivatives are used as prodrugs to improve the membrane permeability of drugs. P-C bond is playing an important role in preserving so many syndromes and in the synthesis of numerous anticancer , antiviral , antimicrobial , anti-diabetic , and antioxidant agents . If the carbon in the P-C bond is aromatic, it acts better than the aliphatic carbon. Quinolines are expressed as LXR mediate disease inhibitors . Quinoline phosphonicdiesters are known for preventing hypercholesterolemia and diabetes . There are number of patents which are dependent on this type of drugs.
Lipinski parameters help in preclinical trials to avoid the tedious and costly procedures that can define them as drugs and to avoid the failure rates. Lipinski parameters suggest the potency of the compounds with a variety of molecular descriptors . The in silico studies involving construction, optimization and molecular dynamics will generate the stable conformations of the molecules. It is also an important task to find out the structure based intermolecular interactions of the compounds with the biologically meaningful and effective targets at specified conditions . This helps to predict the inhibitory activity and the strength of the molecule to form a stable complex with the target. The identification of binding orientations of the compounds in the binding site of target will provide fruitful information on their reactivity. Hence, in the present study we applied Lipinski parameters and molecular docking studies to predict the drug likeliness and binding ability of the compounds to the protein tyrosine phosphatase.
Although several synthetic methods are described for the preparation of such P-C bond containing compounds, one of them is the Michaelis–Arbuzov reaction. Unfortunately, it has some drawbacks when use classical conditions such as length of reaction time, high temperature and removal of the trialkyl phosphite used in a large excess. These drastic conditions may be responsible for side reactions, low yields and limits the application of such reactions to sensitive substrates. Recently, researchers focused on rare earth elemental catalysts due to their high catalytic properties and also act as Lewis acids. In this connection, we selected Lanthanum (III) chloride as an efficient catalyst for nucleophilic substitution on hetero aromatic ring for the synthesis of heteroaryl phosphonicdiamide derivatives via Michaelis-Arbuzov reaction.
The improved production and ineffective scavenging of reactive oxygen species (ROS) cause chemical changes in virtually all cellular components, leading to lipid peroxidation. The enhanced production of free radicals and oxidative stress is central event to the development of diabetic complications. This was supported by demonstration of increased levels of indicators of oxidative stress in diabetic individuals suffering from complications . Oxidative stress is involved in the pathogenesis of diabetes and its complications. Use of antioxidants reduces oxidative stress and alleviates diabetic complications . There are many reports on effects of antioxidants in the management of diabetes ,. So the in vitro antioxidant activity was carried out as preliminary test for all the title compounds. The results of antioxidant activity supported for the reduction of oxidative stress. Finally, title compounds were screened for their in vivo anti-diabetic activity on mice. Most of the title compounds are effective and satisfactory in reducing glucose levels in both the tests.
Chemicals were procured from Sigma–Aldrich and Merck were used as such without further purification. All solvents used for spectroscopic and other physical studies were reagent grade and were further purified by literature methods . Melting points (m p) were determined by Guna Digital Melting Point apparatus using a calibrated thermometer. They expressed in degrees centigrade (°C) and are uncorrected. Infrared spectra (IR) were obtained on a Perkin-Elmer Model 281-B spectrophotometer. Samples were analyzed as potassium bromide (KBr) disks. Absorptions were reported in wave numbers (cm−1). 1H and 13C NMR spectra were recorded as solutions in DMSO-d 6 on a Bruker AMX 400 MHz spectrometer operating at 400 MHz for 1H, 100 MHz for 13C and 161.9 MHz for 31P NMR. The 1H and 13C chemical shifts were expressed in parts per million (ppm) with reference to tetramethylsilane (TMS) and 31P chemical shifts to 85% H3PO4. LCMS mass spectra were recorded on a Jeol SX 102 DA/600 Mass spectrometer.
Synthesis of N,N’-di(4-fluorobenzyl)(2-pyrazinyl)phosphonic diamide (5a)
N,N’-Di(4-fluorobenzyl)(2-pyrazinyl)phosphonic diamide (5a)
Yield: 72%; mp: 162-164°C; IR (KBr): ῡ 3378 (N-H), 1252 (P = O), 1018 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.52-6.84 (11H, m, Ar), 5.12 (2H, brs, H-8), 4.08-3.83 (4H, m, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 161.3 (C-4), 154.3 (C-1), 152.2 (C-1′), 148.9 (C-6′), 145.6 (C-3′), 147.9 (C-4′), 122.4-121.5 (C-2 & C-6), 117.4-116.2 (C-3 & C-5), 31.2 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 28.9; LC MS (%): m/z 375.7 (100%) [MH+•]; Anal. Calcd. for C18H17N4F2OP: C 57.76; H 4.58; N 14.97; Found: C 57.63; H 4.39; N 14.77.
2,4-Dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl-N,N’-di(4-fluorobenzyl)phosphonic diamide (5b)
Yield: 70%; mp: 189-191°C; IR (KBr): ῡ 3386 (N-H), 1238 (P = O), 992 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 9.06 (1H, brs, H-3′), 8.32-6.74 (9H, m, Ar), 5.73-5.68 (1H, s, H-5′), 5.15 (2H, brs, H-8), 3.83-4.08 (4H, m, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 169.6 (C-2′), 161.6 (C-4), 161.3 (C-4′), 158.2 (C-1′), 155.4 (C-1), 141.9 (C-6′), 122.6-121.8 (C-2 & C-6), 117.8-116.8 (C-3 &C-5), 30.9 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 27.6; LC MS (%): m/z 407.8 (100%) [MH+•]; Anal. Calcd. for C18H17N4F2O3P: C 53.21; H 4.22; N 13.79; Found: C 53.08; H 4.12; N 13.55.
N,N’-Di(4-fluorobenzyl)[5-(trifluoromethyl)-2-pyridyl]phosphonic diamide (5c)
Yield: 69%; mp: 202-204°C; IR (KBr): ῡ 3354 (N-H), 1261 (P = O), 1010 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 7.65-6.50 (11H, m, Ar), 5.12 (2H, brs, H-8), 4.06-3.83 (4H, m, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 159.1 (C-4), 155.9 (C-1′), 154.8 (C-3′), 154.0 (C-1), 133.6 (C-5′), 133.5 (C-4′), 122.2-121.1 (C-2 & C-6), 119.6 (C-6′), 118.9 (C-7′), 117.7-116.6 (C-3 & C-5), 30.9 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 28.7; LC MS (%): m/z 442.8 (100%) [MH+•]; Anal. Calcd. for C20H17F5N3OP: C 54.43; H 3.88; N 9.52; Found: 54.15; H 3.51; N 9.22.
N,N’-Di(4-fluorobenzyl)(2-pyrimidinyl)phosphonic diamide (5d)
Yield: 75%; mp: 167-169°C; IR (KBr): ῡ 3346 (N-H), 1268 (P = O), 996 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.55-6.79 (11H, m, Ar), 5.14 (2H, brs, H-8), 4.08-3.83 (4H, m, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 162.5 (C-1′), 161.9 (C-4), 155.1 (C-1), 154.3 (C-3′ & C-5′), 124.4 (C-4′), 121.8-121.1 (C-2 & C-6), 117.6-116.4 (C-3 & C-5), 31.4 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 28.2; LC MS (%): m/z 375.4 (100%) [MH+•]; Anal. Calcd. for C18H17F2N4OP: C 57.76; H 4.58; N 14.97; Found: 57.62; H 4.41; N 14.82.
N,N’-Di(4-fluorobenzyl)(4-isoquinolyl)phosphonic diamide (5e)
Yield: 75%; mp: 221-224°C; IR (KBr): 3364 (N-H), 1274 (P = O), 986 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.65-6.76 (14H, m, Ar), 5.16 (2H, brs, H-8), 4.06-3.84 (4H, m, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 161.6 (C-4), 156.2 (C-4′), 155.2 (C-1), 142.6 (C-2′), 135.9 (C-9′), 129.5 (C-7′), 129.2 (C-10′), 127.5 (C-5′), 127.1 (C-8′), 126.9 (C-6′), 126.2 (C-1′), 122.3-121.5 (C-2 & C-6), 117.7-116.6 (C-3 & C-5), 30.7 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 27.8; LC MS (%): m/z 424.5 (100%) [MH+•]; Anal. Calcd. for C23H20F2N3OP: C 65.25; H 4.76; N 9.92; Found: C 65.09; H 4.57; N 9.71.
N,N’-Di(4-fluorobenzyl)(3-quinolyl)phosphonic diamide (5f)
Yield: 72%; mp: 179-181°C; IR (KBr): 3372 (N-H), 1259 (P = O), 1012 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.63-6.92 (14H, m, Ar), 5.13 (2H, brs, H-8), 4.08-3.83 (4H, m, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 161.5 (C-4), 157.2 (C-9′), 154.5 (C-1), 148.4 (C-2′), 136.8 (C-3′), 131.7 (C-6′), 128.5 (C-4′), 127.3 (C-7′), 126.8 (C-10′), 126.7 (C-5′), 123.6 (C-8′), 122.1-121.3 (C-2 & C-6), 117.8-116.2 (C-3 & C-5), 30.5 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 28.9; LC MS (%): m/z 424.6 (100%) [MH+•]; Anal. Calcd. for C23H20F2N3OP: C 65.25; H 4.76; N 9.92; Found: C 65.08; H 4.51; N 9.84.
Synthesis of 4,6-dimethoxy-1,3,5-triazin-2-yl-N,N’-di(3-pyridylmethyl)phosphonicdiamide (9a)
4,6-Dimethoxy-1,3,5-triazin-2-yl-N,N’-di(3-pyridylmethyl)phosphonic diamide (9a)
Yield: 70%; mp: 198-200°C; IR (KBr): ῡ 3371 (N-H), 1242 (P = O), 989 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.92-7.26 (8H, m, Ar), 5.63 (2H, brs, H-8), 4.39-4.35 (4H, d, H-7), 3.72 (6H, s, -OMe); 13C NMR (100 MHz, DMSO-d 6 ): δ 178.3 (C-3′ & C-5′), 169.2 (C-1′), 149.5 (C-2), 148.1 (C-4), 145.8 (C-1), 135.3 (C-6), 121.5 (C-5), 51.9 (C-OMe), 38.6 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 21.6; LC MS (%): m/z 402.5 (100%) [MH+•]; Anal. Calcd. for C17H20N7O3P: C 50.87; H 5.02; N 24.43; Found: C 50.66; H 4.81; N 24.23.
N,N’-Di(3-pyridylmethyl)(3-quinolyl)phosphonic diamide (9b)
Yield: 74%; mp: 206-208°C; IR (KBr): 3376 (N-H), 1247 (P = O), 1005 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.61-7.46 (14H, m, Ar), 5.64 (2H, brs, H-8), 4.35-4.31 (4H, d, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 149.4 (C-2), 148.9 (C-4), 147.5 (C-2′), 145.2 (C-9′), 135.3 (C-6), 134.6 (C-1), 132.3 (C-3′), 131.7 (C-6′), 128.9 (C-4′), 127.5 (C-5′), 127.3 (C-10′), 126.1 (C-7′), 122.5 (C-8′), 121.7 (C-5), 38.8 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 20.2; LC MS (%): m/z 390.3 (100%) [MH+•]; Anal. Calcd. for C21H20N5OP: C 64.77; H 5.18; N 17.99; Found: C 64.51; H 5.03; N 17.81.
4-Isoquinolyl-N,N’-di(3-pyridylmethyl)phosphonic diamide (9c)
Yield: 73%; mp: 166-169°C; IR (KBr): ῡ 3379 (N-H), 1253 (P = O), 995 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.63-7.45 (14H, m, Ar), 5.62 (2H, brs, H-8), 4.37-4.34 (4H, d, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 152.5 (C-4′), 149.1 (C-2), 148.5 (C-4), 145.2 (C-1), 143.9 (C-2′), 135.1 (C-6), 134.5 (C-9′), 130.2 (C-10′), 129.5 (C-7′), 128.2 (C-6′), 127.4 (C-5′), 127.1 (C-8′), 125.9 (C-1′), 121.3 (C-5), 38.4 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 19.1; LC MS (%): m/z 390.5 (100%) [MH+•]; Anal. Calcd. for C21H20N5OP: C 64.77; H 5.18; N 17.99; Found: C 64.68; H 5.12; N 17.85.
1,3-Benzothiazol-2-yl-N,N’-di(3-pyridylmethyl)phosphonic diamide (9d)
Yield: 66%; mp: 175-177°C; IR (KBr): ῡ 3383 (N-H), 1245 (P = O), 1013 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.48-7.44 (12H, m, Ar), 5.62 (2H, brs, H-8), 4.35-4.31 (4H, d, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 162.2 (C-1′), 155.3 (C-8′), 149.2 (C-2), 148.9 (C-4), 145.5 (C-1), 135.8 (C-6), 134.3 (C-9′), 129.5 (C-4′), 127.1 (C-5′), 125.9 (C-6′), 125.7 (C-3′), 121.2 (C-5), 38.3 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 21.6; LC MS (%): m/z 396.5 (100%) [MH+•]; Anal. Calcd. for C19H18N5OPS: C 57.71; H 4.59; N 17.71; Found: C 57.62; H 4.41; N 17.58.
3-Cyano-2-pyridyl-N,N’-di(3-pyridylmethyl)phosphonic diamide (9e)
Yield: 68%; mp: 172-174°C; IR (KBr): ῡ 3388 (N-H), 1258 (P = O), 1018 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.66-7.41 (11H, m, Ar), 5.63 (2H, brs, H-8), 4.32-4.30 (4H, d, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 157.3 (C-1′), 156.3 (C-3′), 149.3 (C-2), 148.8 (C-4), 145.5 (C-1), 138.4 (C-5′), 135.9 (C-4′), 135.8 (C-6), 121.4 (C-5), 118.3 (C-7′), 113.6 (C-6′), 38.2 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 22.7; LC MS (%): m/z 365.7 (100%) [MH+•]; Anal. Calcd. for C18H17N6OP: C 59.34; H 4.70; N 23.07; Found: C 59.19; H 4.48; N 22.91.
1-Isoquinolyl-N,N’-di(3-pyridylmethyl)phosphonic diamide (9f)
Yield: 73%; mp: 185-187°C; IR (KBr): ῡ 3387 (N-H), 1261 (P = O), 1010 (P-CAr) cm−1; 1H NMR (400 MHz, DMSO-d 6 ): δ 8.61-7.48 (14H, m, Ar), 5.64 (2H, brs, H-8), 4.34-4.31 (4H, d, H-7); 13C NMR (100 MHz, DMSO-d 6 ): δ 159.3 (C-1′), 149.1 (C-2), 148.5 (C-4), 145.9 (C-1), 144.8 (C-3′), 135.9 (C-10′), 135.3 (C-6), 129.7 (C-6′), 129.5 (C-9′), 129.1 (C-8′), 128.5 (C-7′), 127.3 (C-5′), 122.6 (C-4′), 121.7 (C-5), 38.4 (C-7); 31P NMR (161.9 MHz, DMSO-d 6 ): δ 18.9; LC MS (%): m/z 390.2 (100%) [MH+•]; Anal. Calcd. for C21H20N5OP: C 64.77; H 5.18; N 17.99; Found: C 64.55; H 5.02; N 17.75.
All the in silico studies were carried out in the Molecular Operating Environment (MOE) software tool .
Protein preparation and processing
The three dimensional X-Ray Crystallographic structure of Protein tyrosine phosphatase (PTP) was retrieved from Protein Data Bank (PDB ID: 2F71). The structure was loaded into the MOE working environment ignoring the water molecules and hetero atoms. Polar hydrogens were added to the protein and subjected protonation followed by energy minimization in the implicit solvated environment in MMFF94x force field at a gradient cut off value of 0.05. A stabilized conformation of the protein was obtained after energy minimization and it was used for docking study.
The above obtained stable conformation of the protein was preceded with molecular docking process. The binding site was defined with Arg 24, Asp 181, Ser 216, Ala 217, Gly 220, Arg 221 and Arg 254 residues. These are all the residues that were found to be interacting with the previously reported sulfamic acid inhibitor and hence considered for the docking of library of the present novel compounds. All the ligands were docked into the specified binding site using alpha triangle placement methodology where the Poses are generated by superposition of ligand atom triplets and triplets of receptor site points. A random triplet of ligand atoms and a random triplet of alpha sphere centers are used to determine the binding pose at each interaction. The free energy of binding of each compound from each pose generated after docking process is determined by London dG scoring function. A total of 30 conformations were generated for each compound and they were refined and rescored again using the same scoring function. The pose with lowest binding score was selected for further analysis and to analyze the binding mode orientations of the ligands in the binding site.
Pharmacokinetic parameters like absorption, distribution, metabolism and excretion of compounds designates their disposition. Such parameters influence the pharmacokinetics of the drug in the body and in turn influence their performance and pharmacological activity . In that sequence we have predicted some ADMET properties for the designed compounds to define them as drug candidates at their significant conditions. The parameters such as Caco-2 (colon adeno carcinoma) cell permeability, MDCK (Madin-Darby canine kidney) cell permeability, BBB (blood-brain barrier) penetration, HIA (human intestinal absorption), skin permeability and plasma protein binding ability were predicted by submitting the structures to PreADMET online software tool (http://preadmet.bmdrc.org/index.php?option=com_content&view=frontpage&Itemid=1) a web-based application server for predicting ADMET.
Compounds 5a-f and 9a-f were screened for in vitro antioxidant activity by DPPH (2,2-diphenyl-1-picrylhydrazyl), NO and H2O2 methods where Ascorbic acid and BHT (Butylated hydroxytoluene) as standards. Subsequently all the title compounds were screened for their in vivo antihyperglycemic activity in twenty five days period and examined for every four days. The experimental procedures are described below.
DPPH radical scavenging activity
Nitric oxide (NO) scavenging activity
Hydrogen peroxide (H2O2) scavenging activity
Where Acontrol is the absorbance of the control reaction (containing all reagents except the test compound) and Asample is the absorbance of the test compound and Acetate buffer as Ablank.
In vivo antihyperglycemic activity
Induction of diabetes
Male wistar albino rats (body weight 180-200 grams) were subjected to intra-peritoneal administration of Streptozotocin dissolved in freshly prepared 0.01M ice-cold citrate buffer (PH 4.3) at a dose of 50 mg/Kg body weight. After 72 hours, the animals with fasting blood glucose levels ≥350 mg/dL were used to evaluate the anti-diabetic activity of title compounds. Blood glucose levels were measured with the help of Accuchec Glucometer (Glucose oxidase method). All the animals were maintained in ventilated cages provided with standard pellet diet and water in light/dark cycle of (12h/12h) . All of animal experiments were carried out according to the guidelines of the Sri Venkateswara University’s Institutional Animal Care and Use Committee (No./02(i)/a/CPCSCA/IAEC/SVU/TV).
The animals were divided into fifteen groups and each group maintained six rats. Group 1 as normal rats Untreated, Group 2 as diabetic rats Untreated, Group 3 as Diabetic rats treated with standard Glibenclamide (25 mg/kg b.w.) and Group 4-15 as Diabetic rats treated with title compounds (25 mg/kg b.w.) from 5a-f and 9a-f respectively for each group. After an overnight fast, the drug dissolved in DMSO (25 mg/kg b.w.) was fed to 4-15 group rats by gastric intubation using force feeding needle. Normal untreated and diabetic untreated rats were fed with normal diet and distilled water alone. Group 3 diabetic rats were treated with Glibenclamide 25 mg/kg b.w. Blood samples were collected to measure blood glucose levels from the tail vein on 1st, 4th, 8th, 12th, 16th, 20th and 25th days after the administration of drug and blood glucose levels were determined by glucose oxidase–peroxidase method .
The IR spectra of 5a-f showed the expected absorption bands at 998-1008, 3350–3330 and 1255–1233 cm−1 for the P-C(Ar), NH and P = O stretching vibrations respectively . The signals in δ 5.12-5.16 of 5a-f and δ 5.63-5.64 of 9a-f are representing the NH protons attached to the phosphorus atom. All 13C signal of aromatic carbon attached to the phosphorus is observed in between the range of δ 128-139 and δ 152-169. 31P NMR signals appeared in the range of 27.3 to 28.6 ppm as expected for the P = O group of the title compounds.
Prediction of Lipinski parameters
Lipinski parameters of the title compounds 5a-f and 9a-f
Molecular Weight (Daltans)
Hydrogen Bond Donors
Hydrogen Bond Acceptors
Molar Refractivity (Ao3)
Surface area (Ao2)
Hydration energy (K.cal/mol)
Gradient energy (K.cal/molAo)
Total energy (K.cal/mol)
Molecular docking of the title compounds (5a-f and 9a-f) into the PTP biding domain
Docking score (Kcal/mol)
H-bond length (Å)
Arene cat ionic interaction
Arene cat ionic interaction
Arene cat ionic interaction
Arene cat ionic interaction
Arene cat ionic interaction
Arene cat ionic interaction
Arene cat ionic interaction
The HIA results demonstrate the best absorption of the title compounds 5a-f and 9a-f into Human Intestine. Weak plasma protein binding results represent their virtuous properties such as diffusion or transport across cell membranes, interaction with a pharmacological target and excretion. This is due to, generally the drugs less bound to plasma protein exist freely for diffusion or transport across cell membranes and also for interaction with a pharmacological target. The title compounds 9a-j, altogether showed moderate cellular permeability against Caco-2 cells. The compound 5b exhibited medium MDCK cellular permeability. In turn all the above parameters represent their good excretion, disposition and efficacy values in the human body.
The Blood-Brain Barrier (BBB) penetration is represented as BB = [Brain]/[Blood], where [Brain] and [Blood] are the steady-state concentration of radio labeled compound in brain and peripheral blood. Predicting BBB penetration helps to know whether the compounds able to pass across the blood-brain barrier or not. This parameter expresses the BBB penetration capacity and absorption rate of compound to CNS. All the compounds were observed to be having moderate absorption to CNS.
The skin permeability is a crucial parameter that can define the transdermal delivery of the compound as the risk assessment during accidental contact with the skin. The skin permeability values are defined as logKp, cm/hr for all the compounds, where Kp = Km*D/h. Km is distribution coefficient between stratum corneum and vehicle, D is average diffusion coefficient (cm2/h) and h is thickness of skin (cm) .
The title compounds were assessed for anti-oxidant and anti-hyperglycemic activity. The detailed discussion regarding the assessment method is demonstrated as follows.
Free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity
Assay of Nitric oxide radicals scavenging activity
In the current investigation, newly synthesized compounds exhibited an excellent NO radicals scavenging activity. The compounds were evaluated at four different concentrations of 50 μg/mL, 75 μg/mL, 100 μg/mL and 150 μg/mL and the IC50 values were determined from these evaluations. Amongst the title compounds 5e > BHT >5f >5a >5c >9f have exerted significant inhibitory activity and the remaining compounds exhibited less effect than these compounds on radicals that are generated in vitro and the complete results are given in Additional file 1. The IC50 value of each compound was considered as the concentration (μg/mL) of the compound at which 50% of NO reduction was observed. These results are presented in Figure 5 and in Additional file 1: Table S6.
Assay of superoxide radical (O2−) scavenging activity
Superoxide radical is known to be a very harmful species to cellular components as a precursor of more reactive oxygen species . The superoxide radical is known to be produced in vivo and can result in the formation of H2O2via dismutation reaction. Moreover, the conversion of superoxide and H2O2 into more reactive species, for instance, the hydroxyl radical, has been thought to be one of the unfavorable effects caused by superoxide radicals . The newly synthesized compounds are efficient scavengers for the superoxide radical generated in riboflavin–NBT–light system in vitro and their activity is in comparable to that of Ascorbic acid. The compounds were evaluated for their scavenging effects at four different concentrations of 50 μg/mL, 75 μg/mL, 100 μg/mL and 150 μg/mL and the IC50 values were determined from these evaluations. The scavenging effects of the compounds are in the following order 5e >5f >9f >9c > Ascorbic acid and the remaining compounds exhibited less scavenging effect than these compounds on radicals that are generated in vitro. The compounds exhibited almost all same order at all concentrations and the complete results are presented in Additional file 1. This result clearly indicates that the tested compounds have a noticeable effect on scavenging superoxide radical. The IC50 value of each compound was considered as the concentration (μg/mL) of the compound at which 50% of NO reduction was observed. These results are presented in Figure 5 and in Additional file 1: Table S7.
In over view of observation, the compounds 5e, 5f, 9c, 9f are showing the better antioxidant activity, it may be due to the presence of quinolone group in the structures of the title compounds. These results are supported by the previous reports of Shridhar et al. of the antioxidant activity of eight substituted quinolines .
The proposed mechanism for the DPPH radical scavenging activity with the title compounds
Anti-diabetic activity of compounds 5a-f and 9a-f in STZ induced diabetic rats
Glycemic levels(mg/dL) at different time intervals after drug administration to mice
98 ± 1.42 g
97 ± 1.42 g
98 ± 1.42 g
98 ± 1.42 g
99 ± 1.42 g
99 ± 1.42 g
98 ± 1.42 g
365 ± 3.22 ng
364 ± 2.85 ng
366 ± 4.54 ng
360 ± 3.72 ng
364 ± 2.18 ng
362 ± 4.36 ng
361 ± 1.68 ng
355 ± 2.55 n
280 ± 4.85 ng
225 ± 4.58 ng
198 ± 4.25 ng
172 ± 3.25 ng
165 ± 3.85 ng
145 ± 2.76 ng
360 ± 3.44 n
270 ± 3.95 ng
210 ± 4.34 n
179 ± 3.25 ng
135 ± 1.22 n
110 ± 1.85 n
105 ± 2.32 n
372 ± 4.22 ng
250 ± 3.24 n
208 ± 2.85 n
165 ± 2.76 n
138 ± 2.44 n
116 ± 3.08 n
95 ± 2.25
356 ± 4.44 n
312 ± 4.21 ng
250 ± 3.59 ng
221 ± 2.65 ng
200 ± 3.26 ng
193 ± 2.44 ng
178 ± 1.42 ng
364 ± 3.88 n
272 ± 2.66 ng
236 ± 2.88 ng
202 ± 3.11 ng
182 ± 1.35 ng
169 ± 2.52 ng
152 ± 1.43 ng
355 ± 3.14 n
244 ± 2.35 n
212 ± 3.16 n
173 ± 2.42 ng
142 ± 2.35 ng
125 ± 1.56 n
108 ± 1.34 n
359 ± 2.37 n
221 ± 3.25 ng
152 ± 3.46 ng
120 ± 3.15 ng
103 ± 1.47 g
95 ± 1.25 g
82 ± 1.58 ng
362 ± 4.92 n
245 ± 4.86 n
205 ± 2.83 n
146 ± 1.95 ng
132 ± 2.2 ng
123 ± 2.63 n
105 ± 1.73
365 ± 5.22 ng
306 ± 3.58 ng
295 ± 3.64 ng
222 ± 2.95 ng
193 ± 1.45 ng
162 ± 1.73 ng
135 ± 1.34 ng
362 ± 1.85 n
274 ± 4.23 ng
224 ± 2.62 ng
183 ± 3.18 ng
152 ± 1.36 ng
132 ± 1.8 ng
109 ± 1.23 ng
357 ± 2.33 n
255 ± 3.82 ng
205 ± 2.47 n
168 ± 2.68 n
132 ± 1.45 ng
114 ± 1.37 n
98 ± 1.3
363 ± 3.09 n
242 ± 3.42 n
195 ± 3.48 ng
153 ± 2.32 ng
131 ± 1.76 ng
108 ± 1.92 ng
92 ± 1.54 ng
357 ± 2.95 n
245 ± 2.56 n
210 ± 2.45 n
166 ± 2.46 n
137 ± 1.95 n
118 ± 1.83 n
95 ± 2.15 n
The molecules which were bound at Arg24 of Protein tyrosine phosphatase (PTP) gave the potential anti-hyperglycemic properties against Diabetic rats. From these results, compound 9a can be stated as an effective anti-hyperglycemic compound among all as it exerted its effect in the earlier days among all. This may be due to the presence of two methoxy groups on the triazine moiety which are binding at Arg24 of PTP that can make it more reactive and effective. On the 20th day 5b, 5c, 9a, 9e and 9f compounds gave normal glycemic levels, it may be due to the presence of structural moieties like uracil, trifluoromethyl, dimethoxytriazine, nicotinonitrile and quinoline moieties respectively. On the othe other hand the same ligand groups are binding with PTP at Arg24. But a few compounds exhibited moderate results though they contain the quinoline and isoquinoline structures. On an overall, all the compounds have shown good anti-diabetic activities by 25th day except 5a, 5d, 5e and 9c. Over again, these results from molecular docking studies and in vivo assays of the title compounds supporting for previous reports that development of PTPs inhibitors is very ease for diabetes prevention .
Lanthanum (III) chloride is stated as an efficient catalyst for the Michaelis-Arbuzov reaction and for the synthesis of the title compounds 5a-f and 9a-f by two-step reaction. The molecular descriptors of all the compounds from Lipinski parameters explained their drug likeliness and suggesting them as safer drugs. The descriptors also indicate that they are all not harmful to the host system because of their optimal logP values. The molecular docking study revealed their strong ability to interact with the target and inhibits its activity, there by predicting their anti-diabetic activity. PreADMET results demonstrated that the title compounds exhibit good absorption, permeability, penetration abilities in the human body. This prediction is confirmed by in vivo screening of these compounds in the diabetic induced rat models where the test compounds exhibited significant antihyperglycemic activity comparative to the standard Glibenclamide. Almost all the compounds brought the glycemic levels to normal on the 25th day. Especially, 9a was shown normal glycemic levels on 12th day. On the 20th day 5c, 5b, 9a, 9e and 9f were shown normal glycemic levels. All the compounds exhibited good diabetic levels on 25th day except 5a, 5d, 5e and 9c.
Supporting Tables of the antioxidant activity and supporting Figures are given in the supporting information as Additional file 1.
The authors express their grateful thanks to BRNS (DAE) for sanctioning research project (2012/37C/21/BRNS/785), Mumbai, India for providing financial assistance through the project.
- Kennedy BP, Ramachandran C: Protein tyrosine phosphatase-1B in diabetes. Biochem Pharmacol. 2000, 60: 877-883. 10.1016/S0006-2952(00)00305-1.View ArticlePubMedGoogle Scholar
- Johnson TO, Ermolieff J, Jirousek MR: Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Disc. 2002, 1: 696-709. 10.1038/nrd895.View ArticleGoogle Scholar
- Wang Q, Gao J, Liu Y, Liu C: Molecular dynamics simulation of the interaction between protein tyrosine phosphatase 1B and aryl diketoacid derivatives. J Mol Graph Model. 2012, 38: 186-193. 10.1016/j.jmgm.2012.06.011.View ArticlePubMedGoogle Scholar
- Evans JL, Jallal B: Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Exp Opin Invest Drugs. 1999, 8: 139-160. 10.1517/13543718.104.22.168.View ArticleGoogle Scholar
- Cheng A, Dube N, Gu F, Tremblay ML: Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur J Biochem. 2002, 269: 1050-1059. 10.1046/j.0014-2956.2002.02756.x.View ArticlePubMedGoogle Scholar
- Liu G, Xin Z, Liang H, Zapatero CA, Hajduk PJ, Janowick DA, Szczepankiewicz BG, Pei Z, Hutchins CW, Ballaron SJ, Stashko MA, Lubben TH, Berg CE, Rondinone CM, Trevillyan JM, Jirousek MR: Selective protein tyrosine phosphatase-1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem. 2003, 46: 3437-3440. 10.1021/jm034088d.View ArticlePubMedGoogle Scholar
- Wan ZK, Lee J, Xu W, Erbe DV, McCarthy DJ, Follows BC, Zhang Y: Monocyclic thiophenes as protein tyrosine phosphatase-1B inhibitors: capturing interactions with Asp48. Bioorg Med Chem Lett. 2006, 16: 4941-4945. 10.1016/j.bmcl.2006.06.051.View ArticlePubMedGoogle Scholar
- Liu G, Xin Z, Pei Z, Hajduk PJ, Zapatero CA, Hutchins CW, Hongyu ZH, Lubben TH, Ballaron SJ, Haasch DL, Kaszubska W, Rondinone CM, Trevillyan JM, Jirousek MR: Selective protein tyrosine phosphatase-1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands. J Med Chem. 2003, 46: 4232-4235. 10.1021/jm034122o.View ArticlePubMedGoogle Scholar
- Shim YS, Kim KC, Chi DY, Lee KH, Cho H: Formylchromone derivatives as a novel class of protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett. 2003, 13: 2561-2563. 10.1016/S0960-894X(03)00479-7.View ArticlePubMedGoogle Scholar
- Adams DR, Abraham A, Asano J, Breslin C, Dick CAJ, Lxkes U, Johnston BF, Johnston D, Kewnay J, Mackay SP, Mackenzie SJ, Mcfarlane M, Mitchell L, Takano Y: 2-Aryl-3,3,3-trifluoro-2-hydroxypropionic acids: a new class of protein tyrosine phosphatase-1B inhibitors. Bioorg Med Chem Lett. 2007, 17: 6579-6583. 10.1016/j.bmcl.2007.09.069.View ArticlePubMedGoogle Scholar
- Qingming W, Miaoli Z, Ruiting Z, Liping L, Caixia Y, Shu X, Xueqi F, Yuhua M, Qingwei H: Exploration of α-aminophosphonate N-derivatives as novel, potent and selective inhibitors of protein tyrosine phosphatases. Eur J Med Chem. 2012, 49: 354-364. 10.1016/j.ejmech.2012.01.038.View ArticleGoogle Scholar
- Zsuzsa I, Estelle W, Almudena L, Maria PP, Federica P, Eva S, Sandy B, John W, Fermin IM, Alfredo Martinez J, Philippe V, Christian C: Chronic benzylamine administration in the drinking water improves glucose tolerance, reduces body weight gain and circulating cholesterol in high-fat diet-fed mice. Pharmacol Res Off J Italian Pharmacol Soc. 2010, 61: 355-363. 10.1016/j.phrs.2009.12.014.View ArticleGoogle Scholar
- Stefan M, Robert W, Bernhard S, Susanne K, Roger A: Picolylamine-methylphosphonic acid esters as tridentate ligands for the labeling of alcohols with the fac-[M(CO)3]+ core (M = 99mTc, Re): synthesis and biodistribution of model compounds and of a 99mTc-labeled cobinamide. Nuclear Med Biol. 2005, 32: 473-484. 10.1016/j.nucmedbio.2005.04.007.View ArticleGoogle Scholar
- Simon TB, Karen RB, Teresa B, Ijen C, Mike C, Sarah D, Tim H, Allan MJ, Guy AK, Anthony RK, Burkhard K, Loic L, Angela M, Anil M, Sean L, Anthony P, Karine P, Mark R, Heather S, Melanie W, Ian AY: Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor. Bioorg Med Chem Lett. 2009, 19: 5945-5949. 10.1016/j.bmcl.2009.08.040.View ArticleGoogle Scholar
- Phillip JK, Thomas MB, Patrick RG, John TB, Alexander SK, Carrie KJ, Ashley EB, Jana KS, Jeffrey CP, Craig WL: Synthesis and structure–activity relationships of allosteric potentiators of the M4 muscarinic acetylcholine receptor. Chem Med Chem. 2009, 4: 1600-1607. 10.1002/cmdc.200900231.View ArticleGoogle Scholar
- Y Patrick YSL, Yu R, Prabhakar KJ, Paul EA, George VD, Charles JE, Chong HC, George E, Edward RH, Wayne FD, Liangzhu L, Pat NC, Robert JM, Qi H, Renhua L, Jay AM, Steven PS, Thomas RS, Lee TB, Marlene MR, Ronald MK, Linyee S, Dean LW, David MK, David AJ, Erickson-Viitanen S, Nicholas Hodge C: Cyclic HIV protease inhibitors: synthesis, conformational analysis, P2/P2¢ structure-activity relationship and molecular recognition of cyclic ureas. J Med Chem. 1996, 39: 3514-3525. 10.1021/jm9602571.View ArticleGoogle Scholar
- Jones BCNM, McGuigan C, O’Connor TJ, Jeffries DJ, Kinchington D: Synthesis and anti-HIV activity of some novel phosphoradiamidate derivatives of 3′-azido-3′-deoxythymidine (AZT). AntiVir Chem Chemother. 1991, 2: 35-39.View ArticleGoogle Scholar
- Serafinowska HT, Ashton RJ, Bailey S, Harnden MR, Jackson SM, Sutton D: Synthesis and in vivo evaluation of prodrugs of 9-[2-(phosphonomethoxy)ethoxy] adenine. J Med Chem. 1995, 38: 1372-1379. 10.1021/jm00008a015.View ArticlePubMedGoogle Scholar
- Keith KA, Hitchcock MJ, Lee WA, Holy A, Kern ER: Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob Agents Chemother. 2003, 47: 2193-2198. 10.1128/AAC.47.7.2193-2198.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Petr J, Ondrej B, Martin D, Ivan V, Zdenek Z, Gina B, George S, Tomas C, Richard M, Antonin H, Zlatko J: A novel and efficient one-pot synthesis of symmetrical diamide (bis-amidate) prodrugs of acyclic nucleoside phosphonates and evaluation of their biological activities. Eur J Med Chem. 2008, 46: 3748-3754.Google Scholar
- Qun D, Rao KS, Tao J, Kevin F, Yan L, Frank T, William S, Daniel KC, Reddy KR, Paul DP, James MF, Scott CP, Mark DE: Discovery of phosphonicdiamideprodrugs and their use for the oral delivery of a series of fructose 1,6-bisphosphatase inhibitors. J Med Chem. 2008, 51: 4331-4339. 10.1021/jm8001235.View ArticleGoogle Scholar
- Claude G, Nicolas B, Chantal F, Raphael ED: Synthesis and antibacterial activity of novel enolphosphate derivatives. Bioorg Chem. 2010, 38: 218-223. 10.1016/j.bioorg.2010.06.006.View ArticleGoogle Scholar
- Asish KB, Florian S, Schmidt R: Design and synthesis of aryl/hetarylmethylphosphonate-UMP derivatives as potential glucosyltransferase inhibitors. Tetrahedron Lett. 2001, 42: 5393-5395. 10.1016/S0040-4039(01)00974-1.View ArticleGoogle Scholar
- Salkeeva LK, Nurmaganbetova MT, Minaeva EV, Kokzhalova BZ: Reactions of tert-Butyl N, N-Diethyl-N -(4-phenylthiazol-2-yl)-phosphorodiamidite with electrophilic reagents. Russ J Gen Chem. 2006, 76: 1397-1400. 10.1134/S1070363206090076.View ArticleGoogle Scholar
- Michael DC, Robert RS, Baihua H, James WJ, Robrt LM, David HK, Miller CP, Ullrich JW, Unwalla RJ, Wrobel JE, Quinet E, Nambai P, Bernotas RC, Elloso M: Anticholesterol Agents; Antidiabetic Agents; Cardiovascular Disorders; Antiarthritic Agents. 2009Google Scholar
- Miyata K, Shoji Y, Tsuda Y, Tsutsumi K, Kamisaka E, Inoue Y: Inoue, JP-A-5043589. In ᅟ. ; 1993. http://www.wikipatents.com/JP-Patent-5043589/quinoline-derivative.
- Nallusamy S, Samuel S: QSAR studies on HIV-1 protease inhibitors using Non-linearly transformed descriptors. Curr Comput Aided Drug Des. 2012, 8: 10-49. 10.2174/157340912799218534.View ArticleGoogle Scholar
- Valasani KR, Hu G, Chaney MO, Yan SS: Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer’s disease. Chem Biol Drug Des. 2013, 81 (2): 238-249. 10.1111/cbdd.12068.PubMed CentralView ArticlePubMedGoogle Scholar
- Ehsaneh T, Mahmoud D, Ahmad S, Ali MM, Djazayeri A, Qorbani M: The relationship between the activates of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects. J Diab Metabol Disord. 2012, 11: 1-5. 10.1186/2251-6581-11-1.View ArticleGoogle Scholar
- Roja R, Shekoufeh N, Bagher L, Mohammad A: A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005, 59: 365-373. 10.1016/j.biopha.2005.07.002.View ArticleGoogle Scholar
- Suresh K, Sunil S, Vasudeva N, Varun R:In vivo anti-hyperglycemic and antioxidant potentials of ethanolic extract from Tecomella undulate. Diabetol Metabol Syndrome. 2012, 4: 1-7. 10.1186/1758-5996-4-1.View ArticleGoogle Scholar
- V Jan V, Marek J, Travnicek Z, Racanska E, Muselik J, Svajlenova O: Synthesis, structural characterization, antiradical and antidiabetic activities of copper(II) and Zinc(II) Schiff’s base complexes derived from salicylaldehyde and β-alanine. J Inorg Biochem. 2008, 102: 595-605. 10.1016/j.jinorgbio.2007.10.003.View ArticleGoogle Scholar
- Armarego WLF, Perrin DD: Purification of Laboratory Chemicals. 1997, Butterworth, Heinemann, Oxford, 4Google Scholar
- Molecular Operating Environment (MOE): 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7: 2011.10; Chemical Computing Group Inc; 2011.Google Scholar
- Beresford AP, Selick HE, Tarbit MH: The emerging importance of predictive ADME simulation in drug discovery. Drug Discov Today. 2002, 7 (2): 109-116. 10.1016/S1359-6446(01)02100-6.View ArticlePubMedGoogle Scholar
- Marcocci L, Maguire JJ, Droy Lefaix MT, Packer L: The nitric oxide-scavenging properties of ginkgo biloba extract EGb 761. Biochem Biophys Res Commun. 1994, 201: 748-755. 10.1006/bbrc.1994.1764.View ArticlePubMedGoogle Scholar
- Ruch RJ, Cheng SJ: Klaunig: prevention of cytotoxicity and inhibition of intercellular communication by antioxidant catechins isolated from Chinese green tea. Carcinogenesis. 1989, 10: 1003-1008. 10.1093/carcin/10.6.1003.View ArticlePubMedGoogle Scholar
- Magid AFA, Carson KG, Harris BD, Maryanoff CA, Shah RD: Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. studies on direct and indirect reductive amination procedures. J Org Chem. 1996, 61: 3849-3862. 10.1021/jo960057x.View ArticlePubMedGoogle Scholar
- Kesari AN, Gupta RK, Singh SK, Diwakar S, Watal G: Hypoglycemic and anti-hyperglycemic activity of Aeglemarmelos seed extract in normal and diabetic rats. J Ethnopharmacol. 2006, 107: 374-379. 10.1016/j.jep.2006.03.042.View ArticlePubMedGoogle Scholar
- Thomas LCP: Interpretation of the Infrared Spectra of Organophosphorus Compounds. 1974, Hyden and Son Ltd, LondonGoogle Scholar
- Rao VK, Michael OC, Victor WD, Yan SS: Acetylcholinesterase inhibitors: structure based design, synthesis, pharmacophore modeling, and virtual screening. J Chem Inf Model. 2013, 53 (8): 2033-2046. 10.1021/ci400196z.View ArticleGoogle Scholar
- Gulcin I, Bursal E, Hilal M, Ehitoglu S, Bilsel M, Goren AC: Polyphenol contents and antioxidant activity of lyophilized aqueous extract of propolis from Erzurum, Turkey. Food Chem Toxic. 2010, 48: 2227-2230. 10.1016/j.fct.2010.05.053.View ArticleGoogle Scholar
- Soares JR, Dins TCP, Cunha AP, Ameida LM: Antioxidant activity of some extracts of Thymus zygis. Free Rad Res. 1986, 26: 469-478. 10.3109/10715769709084484.View ArticleGoogle Scholar
- B Halliwell B, Gutteridge JMC: In Free Radicals, Ageing, and Disease, Free Radicals in Biology and Medicine. 2007, Clarendron Press, Oxford, 4Google Scholar
- Halliwell B: Reactive oxygen species in living systems source, biochemistry, and role in human disease. Am J Med. 1991, 91: 14-22. 10.1016/0002-9343(91)90279-7.View ArticleGoogle Scholar
- Shridhar AH, Keshavayya J, Peethambar SK, Hoskeri JH: Synthesis and Biological activity of Bis alkyl 1,3,4-oxadiazole incorporated azo dye derivatives. Arab J Chem 2012. http://dx.doi.org/10.1016/j.arabjc.2012.04.018.
- Osman H, Arshad A, Lam CK, Bagley MC: Microwave assisted synthesis and antioxidant properties of hydrazinylthiazolylcoumarin derivatives. Chem Centr J. 2012, 6: 32-41. 10.1186/1752-153X-6-32.View ArticleGoogle Scholar
- Safavi M, Foroumadi A, Abdollahi M: The importance of synthetic drugs for type 2 diabetes drug discovery. Expert Opin Drug Discov. 2013, 8 (11): 1339-1363. 10.1517/17460441.2013.837883.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.